Antimalarial procurement in private-sector pharmaceutical outlets: decision-making complexities and implications for medicine quality in Tanzania
- PMID: 37696543
- PMCID: PMC10514607
- DOI: 10.1136/bmjgh-2022-010821
Antimalarial procurement in private-sector pharmaceutical outlets: decision-making complexities and implications for medicine quality in Tanzania
Abstract
Poor-quality medicines are a major threat to healthcare provision in low-income countries. The problem exacerbates disease vulnerabilities of already disadvantaged populations including children, women, and the elderly. However, while the higher-level structural drivers of this problem are well established, little is known about decision-making lower down pharmaceutical supply chains, and whether this might produce vulnerabilities for medicine quality. We conducted a mixed-methods study to explore retailer-supplier interactions and decision-making dynamics for antimalarial medicines in three regions of Tanzania: Tabora, Dodoma and Mbeya. A survey questionnaire was administered to 118 small scale-and mid-range retailers in urban and rural districts of the regions. We then conducted 12 in-depth interviews with staff and owners of medicine outlets in 2 districts of Tabora region to explore further the decision-making dynamics. Results show that private-sector retailers are driven first and foremost by business and economic practicalities when choosing a medicine supplier, prioritising low purchase price, free delivery, and availability of credit. Many also rely on suppliers with whom they have personal connections, developed either within or outside the business context. Medicine quality comes far lower down the list of priorities. These findings are perhaps not surprising in a context where businesses serving low-income customers are operating on very small margins. However, when price and personal connection eclipse any other considerations, there is a risk that poor-quality medicines may find their way into supply chains, especially in countries where regulatory capacity is limited, and pharmaceutical supply chains are complex and opaque.
Keywords: cross-sectional survey; health systems; malaria; public health; qualitative study.
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Antimalarial stocking decisions among medicine retailers in Ghana: implications for quality management and control of malaria.BMJ Glob Health. 2023 Sep;6(Suppl 3):e013426. doi: 10.1136/bmjgh-2023-013426. BMJ Glob Health. 2023. PMID: 37734858 Free PMC article.
-
Understanding private sector antimalarial distribution chains: a cross-sectional mixed methods study in six malaria-endemic countries.PLoS One. 2014 Apr 3;9(4):e93763. doi: 10.1371/journal.pone.0093763. eCollection 2014. PLoS One. 2014. PMID: 24699934 Free PMC article.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Jazia prime vendor system- a public-private partnership to improve medicine availability in Tanzania: from pilot to scale.J Pharm Policy Pract. 2019 Feb 25;12:4. doi: 10.1186/s40545-019-0163-4. eCollection 2019. J Pharm Policy Pract. 2019. PMID: 30891247 Free PMC article.
-
Assessing public-private procurement practices for medical commodities in Dar Es Salaam: a situation analysis.BMC Health Serv Res. 2022 Dec 14;22(1):1523. doi: 10.1186/s12913-022-08923-1. BMC Health Serv Res. 2022. PMID: 36517787 Free PMC article. Review.
References
-
- WHO . Study on the public health & socioeconomic impact of SF medical products. Geneva: World Health Organisation, 2017.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources